NASDAQ:EYEG - Eyegate Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eyegate Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.15 +0.09 (+1.49 %) (As of 01/28/2020 04:00 PM ET) Add Compare Today's Range$6.00Now: $6.15▼$6.2650-Day Range$5.63MA: $7.79▼$12.2052-Week Range$2.25Now: $6.15▼$12.89Volume31,800 shsAverage Volume109,133 shsMarket Capitalization$24.90 millionP/E RatioN/ADividend YieldN/ABeta2.62 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYEG Previous Symbol CUSIPN/A CIK1372514 Webhttp://www.eyegatepharma.com/ Phone781-788-8869Debt Debt-to-Equity RatioN/A Current Ratio1.43 Quick Ratio1.43Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.65 million Price / Sales15.09 Cash FlowN/A Price / Cash FlowN/A Book Value$3.08 per share Price / Book2.00Profitability EPS (Most Recent Fiscal Year)($4.50) Net Income$-10,810,000.00 Net MarginsN/A Return on Equity-84.78% Return on Assets-59.56%Miscellaneous Employees11 Outstanding Shares4,049,000Market Cap$24.90 million Next Earnings Date3/6/2020 (Estimated) OptionableNot Optionable Receive EYEG News and Ratings via Email Sign-up to receive the latest news and ratings for EYEG and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:EYEG Rates by TradingView Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions What is Eyegate Pharmaceuticals' stock symbol? Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG." How were Eyegate Pharmaceuticals' earnings last quarter? Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) announced its quarterly earnings data on Thursday, November, 7th. The specialty pharmaceutical company reported ($1.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.75) by $0.40. View Eyegate Pharmaceuticals' Earnings History. When is Eyegate Pharmaceuticals' next earnings date? Eyegate Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 6th 2020. View Earnings Estimates for Eyegate Pharmaceuticals. Has Eyegate Pharmaceuticals been receiving favorable news coverage? News articles about EYEG stock have been trending positive on Tuesday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eyegate Pharmaceuticals earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Eyegate Pharmaceuticals. Who are some of Eyegate Pharmaceuticals' key competitors? Some companies that are related to Eyegate Pharmaceuticals include Aquestive Therapeutics (AQST), Cyclerion Therapeutics (CYCN), AVEO Pharmaceuticals (AVEO), Stealth BioTherapeutics (MITO), Bellicum Pharmaceuticals (BLCM), Sesen Bio (SESN), Enlivex Therapeutics (ENLV), Trevi Therapeutics (TRVI), Oramed Pharmaceuticals (ORMP), Proteostasis Therapeutics (PTI), Neos Therapeutics (NEOS), Immunic (IMUX), Trevena (TRVN), Inflarx (IFRX) and Synlogic (SYBX). What other stocks do shareholders of Eyegate Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eyegate Pharmaceuticals investors own include Bausch Health Companies (BHC), MannKind (MNKD), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Canopy Growth (CGC), Arca Biopharma (ABIO) and Anavex Life Sciences (AVXL). Who are Eyegate Pharmaceuticals' key executives? Eyegate Pharmaceuticals' management team includes the folowing people: Mr. Stephen From, Pres, CEO & Director (Age 56)Dr. Barbara M. Wirostko, Chief Medical Officer (Age 53)Mr. Michael P. Manzo, VP of Engineering (Age 60)Ms. Sarah Romano, Chief Financial OfficerDr. MaryJane Rafii Ph.D., Consultant When did Eyegate Pharmaceuticals IPO? (EYEG) raised $5 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO. How do I buy shares of Eyegate Pharmaceuticals? Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Eyegate Pharmaceuticals' stock price today? One share of EYEG stock can currently be purchased for approximately $6.15. How big of a company is Eyegate Pharmaceuticals? Eyegate Pharmaceuticals has a market capitalization of $24.90 million and generates $1.65 million in revenue each year. The specialty pharmaceutical company earns $-10,810,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis. Eyegate Pharmaceuticals employs 11 workers across the globe.View Additional Information About Eyegate Pharmaceuticals. What is Eyegate Pharmaceuticals' official website? The official website for Eyegate Pharmaceuticals is http://www.eyegatepharma.com/. How can I contact Eyegate Pharmaceuticals? Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869. MarketBeat Community Rating for Eyegate Pharmaceuticals (NASDAQ EYEG)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 391 (Vote Outperform)Underperform Votes: 317 (Vote Underperform)Total Votes: 708MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYEG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: What member countries make up the G-20?
